Insulin analogs with improved pharmacokinetic profiles.

[1]  J L Whittingham,et al.  Interactions of phenol and m-cresol in the insulin hexamer, and their effect on the association properties of B28 pro --> Asp insulin analogues. , 1998, Biochemistry.

[2]  R. Guy,et al.  Iontophoresis of monomeric insulin analogues in vitro: effects of insulin charge and skin pretreatment. , 1998, Journal of controlled release : official journal of the Controlled Release Society.

[3]  B. Frier,et al.  Optimal Time of Administration of Insulin Lispro. Importance of meal composition , 1998, Diabetes Care.

[4]  P. Home,et al.  The Effect of the Insulin Analog Lispro on Nighttime Blood Glucose Control in Type 1 Diabetic Patients , 1998, Diabetes Care.

[5]  L. Vignati,et al.  Basal activity profiles of NPH and [Nɛ-palmitoyl Lys (B29)] human insulins in subjects with IDDM , 1998, Diabetologia.

[6]  R. Heine,et al.  Nighttime Insulin Kinetics and Glycemic Control in Type 1 Diabetes Patients Following Administration of an Intermediate-Acting Lispro Preparation , 1997, Diabetes Care.

[7]  F. Holleman,et al.  Reduced Frequency of Severe Hypoglycemia and Coma in Well-Controlled IDDM Patients Treated With Insulin Lispro , 1997, Diabetes Care.

[8]  L. Heinemann,et al.  Insulin Aspart in a 30/70 Premixed Formulation: Pharmacodynamic properties of a rapid-acting insulin analog in stable mixture , 1997, Diabetes Care.

[9]  M. Feinglos,et al.  Modification of Postprandial Hyperglycemia With Insulin Lispro Improves Glucose Control in Patients With Type 2 Diabetes , 1997, Diabetes Care.

[10]  D. Kumar.  Lispro Analog for Treatment of Generalized Allergy to Human Insulin , 1997, Diabetes Care.

[11]  R. Heine,et al.  Metabolic Efficacy of Preprandial Administration of Lys(B28), Pro(B29) Human Insulin Analog in IDDM Patients: A comparison with human regular insulin during a three-meal test period , 1997, Diabetes Care.

[12]  P. Jansson,et al.  Strategies Toward Improved Control During Insulin Lispro Therapy in IDDM: Importance of basal insulin , 1997, Diabetes Care.

[13]  B. Zinman,et al.  Stability of Insulin Lispro in Insulin Infusion Systems , 1997, Diabetes Care.

[14]  L. Vignati,et al.  Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with non-insulin-dependent diabetes mellitus. Multicenter Insulin Lispro Study Group. , 1997, Archives of internal medicine.

[15]  J. Clore,et al.  Mixing Insulin Lispro and Ultralente Insulin , 1997, Diabetes Care.

[16]  L. Vignati,et al.  Health-Related Quality-of-Life Results From Multinational Clinical Trials of Insulin Lispro: Assessing benefits of a new diabetes therapy , 1997, Diabetes Care.

[17]  L. Heinemann,et al.  Are presently available insulin analogues clinically beneficial? , 1997, Diabetologia.

[18]  L. Slieker,et al.  Modifications in the B10 and B26–30 regions of the B chain of human insulin alter affinity for the human IGF-I receptor more than for the insulin receptor , 1997, Diabetologia.

[19]  J. Brange,et al.  The new era of biotech insulin analogues , 1997, Diabetologia.

[20]  J. Brange,et al.  Toward understanding insulin fibrillation. , 1997, Journal of pharmaceutical sciences.

[21]  R. DiMarchi,et al.  Bioavailability and Bioeffectiveness of Subcutaneous Human Insulin and Two of its Analogs—LysB28ProB29-Human Insulin and AspB10LysB28ProB29-Human Insulin—Assessed in a Conscious Pig Model , 1997, Diabetes.

[22]  S. R. Myers,et al.  Acylation of Human Insulin With Palmitic Acid Extends the Time Action of Human Insulin in Diabetic Dogs , 1997, Diabetes.

[23]  J. Whittingham,et al.  Crystal structure of a prolonged-acting insulin with albumin-binding properties. , 1997, Biochemistry.

[24]  B. Zinman,et al.  Insulin Lispro in CSII: Results of a Double-Blind Crossover Study , 1997, Diabetes.

[25]  M. Burge,et al.  Prolonged efficacy of short acting insulin Lispro in combination with human ultralente in insulin-dependent diabetes mellitus. , 1997, The Journal of clinical endocrinology and metabolism.

[26]  N. Bohannon.  Benefits of lispro insulin: control of postprandial glucose levels is within reach. , 1997, Postgraduate medicine.

[27]  M. Burge,et al.  Meal Composition is a Determinant of Lispro-Induced Hypoglycemia in IDDM , 1997, Diabetes Care.

[28]  L. Vignati,et al.  Reduction of Postprandial Hyperglycemia and Frequency of Hypoglycemia in IDDM Patients on Insulin-Analog Treatment , 1997, Diabetes.

[29]  M. Knip,et al.  Severe Antibody-Mediated Human Insulin Resistance: Successful Treatment With the Insulin Analog Lispro: A case report , 1997, Diabetes Care.

[30]  L. Vignati,et al.  Improved mealtime treatment of diabetes mellitus using an insulin analogue. Multicenter Insulin Lispro Study Group. , 1997, Clinical therapeutics.

[31]  M. Trautmann,et al.  Intensive insulin therapy with insulin lispro in patients with type 1 diabetes reduces the frequency of hypoglycemic episodes. , 2009, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[32]  J. Thijssen,et al.  Injection Site Effects on the Pharmacokinetics and Glucodynamics of Insulin Lispro and Regular Insulin , 1996, Diabetes Care.

[33]  J. M. Beals,et al.  Physicochemical basis for the rapid time‐action of LysB28ProB29‐insulin: Dissociation of a protein‐ligand complex , 1996, Protein science : a publication of the Protein Society.

[34]  N. Fineberg,et al.  Immunologic Effects of Insulin Lispro [Lys (B28), Pro (B29) Human Insulin] in IDDM and NIDDM Patients Previously Treated With Insulin , 1996, Diabetes.

[35]  M. Trautmann,et al.  Severe insulin resistance treated with insulin lispro , 1996, The Lancet.

[36]  P. Brunetti,et al.  Effects of the Short-Acting Insulin Analog [Lys(B28),Pro(B29)] on Postprandial Blood Glucose Control in IDDM , 1996, Diabetes Care.

[37]  L Heinemann,et al.  Prandial Glycaemia After a Carbohydrate‐rich Meal in Type I Diabetic Patients: Using the Rapid Acting Insulin Analogue [Lys(B28), Pro(B29)] Human Insulin , 1996, Diabetic medicine : a journal of the British Diabetic Association.

[38]  H. Chase,et al.  Pre‐meal Insulin Analogue Insulin Lispro vs Humulin® R Insulin Treatment in Young Subjects with Type 1 Diabetes , 1996, Diabetic medicine : a journal of the British Diabetic Association.

[39]  U. Ribel,et al.  Albumin binding of insulins acylated with fatty acids: characterization of the ligand-protein interaction and correlation between binding affinity and timing of the insulin effect in vivo. , 1995, The Biochemical journal.

[40]  U. Ribel,et al.  Action Profile of Cobalt(III)-Insulin: A Novel Principle of Protraction of Potential Use for Basal Insulin Delivery , 1995, Diabetes.

[41]  L. Heinemann,et al.  Time-action profiles of the intermediate-acting insulin analogue des(64,65)-human proinsulin. , 1995, Diabete & metabolisme.

[42]  P. Brunetti,et al.  Improved Postprandial Metabolic Control After Subcutaneous Injection of a Short-Acting Insulin Analog in IDDM of Short Duration With Residual Pancreatic β-Cell Function , 1995, Diabetes Care.

[43]  P. Kurtzhals,et al.  The cobalt(III)-insulin hexamer is a prolonged-acting insulin prodrug. , 1995, Journal of pharmaceutical sciences.

[44]  D. Howey,et al.  [Lys(B28), Pro(B29)]‐human insulin: Effect of injection time on postprandial glycemia , 1995, Clinical pharmacology and therapy.

[45]  F. Gries,et al.  Insulinkinetic and -Dynamic in Diabetic Patients Under Insulin Pump Therapy After Injections of Human Insulin or the Insulin Analogue (B28Asp) , 1995, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[46]  J. M. Beals,et al.  Role of C-terminal B-chain residues in insulin assembly: the structure of hexameric LysB28ProB29-human insulin. , 1995, Structure.

[47]  D. Howey,et al.  [Lys(B28), Pro(B29)]-Human Insulin: A Rapidly Absorbed Analogue of Human Insulin , 1994, Diabetes.

[48]  L. Slieker,et al.  Preparation of an insulin with improved pharmacokinetics relative to human insulin through consideration of structural homology with insulin-like growth factor I. , 1994, Hormone research.

[49]  Z Trajanoski,et al.  Pharmacokinetic Model for the Absorption of Subcutaneously Injected Soluble Insulin and Monomeric Insulin - Analogues - Pharmakokinetisches Modell für die Absorption von subkutan injiziertem löslichem Insulin und monomeren Insulinanaloga , 1993, Biomedizinische Technik. Biomedical engineering.

[50]  L. Heinemann,et al.  Action Profile of the Rapid Acting Insulin Analogue: Human Insulin B28Asp , 1993, Diabetic medicine : a journal of the British Diabetic Association.

[51]  E J Dodson,et al.  Role of B13 Glu in insulin assembly. The hexamer structure of recombinant mutant (B13 Glu-->Gln) insulin. , 1992, Journal of molecular biology.

[52]  K. Drejer.  The bioactivity of insulin analogues from in vitro receptor binding to in vivo glucose uptake. , 1992, Diabetes/metabolism reviews.

[53]  B H Frank,et al.  Altering the association properties of insulin by amino acid replacement. , 1992, Protein engineering.

[54]  E. Dodson,et al.  Mutant insulin crystal packing , 1992 .

[55]  D. Howey,et al.  Biosynthetic Human Proinsulin: Review of Chemistry, in Vitro and in Vivo Receptor Binding, Animal and Human Pharmacology Studies, and Clinical Trial Experience , 1992, Diabetes Care.

[56]  S. Shoelson,et al.  Mutations at the dimer, hexamer, and receptor-binding surfaces of insulin independently affect insulin-insulin and insulin-receptor interactions. , 1992, Biochemistry.

[57]  J. Brange,et al.  Designing insulin for diabetes therapy by protein engineering , 1992, Current Biology.

[58]  D. Brems,et al.  Synthesis of a Fast-Acting Insulin Based on Structural Homology with Insulin-Like Growth Factor I, , 1992 .

[59]  J. Brange,et al.  Chemical stability of insulin. 3. Influence of excipients, formulation, and pH. , 1992, Acta pharmaceutica Nordica.

[60]  D R Owens,et al.  Absorption Kinetics and Action Profiles of Subcutaneously Administered Insulin Analogues (AspB9GluB27, AspB10, AspB28) in Healthy Subjects , 1991, Diabetes Care.

[61]  U. Ribel,et al.  In Vitro and In Vivo Potency of Insulin Analogues Designed for Clinical Use , 1991, Diabetic medicine : a journal of the British Diabetic Association.

[62]  D R Owens,et al.  Subcutaneous Insulin Absorption Explained by Insulin's Physicochemical Properties: Evidence From Absorption Studies of Soluble Human Insulin and Insulin Analogues in Humans , 1991, Diabetes Care.

[63]  S. Shoelson,et al.  Heteronuclear 2D NMR studies of an engineered insulin monomer: assignment and characterization of the receptor-binding surface by selective 2H and 13C labeling with application to protein design. , 1991, Biochemistry.

[64]  D. Owens,et al.  Comparison of Subcutaneous Soluble Human Insulin and Insulin Analogues (AspB9, GluB27; AspB10; AspB28) on Meal-Related Plasma Glucose Excursions in Type I Diabetic Subjects , 1991, Diabetes Care.

[65]  D R Owens,et al.  Monomeric Insulins and Their Experimental and Clinical Implications , 1990, Diabetes Care.

[66]  P. Hougaard,et al.  Equivalent In Vivo Biological Activity of Insulin Analogues and Human Insulin Despite Different In Vitro Potencies , 1990, Diabetes.

[67]  M. Roy,et al.  Sequence-specific 1H-NMR assignments for the aromatic region of several biologically active, monomeric insulins including native human insulin. , 1990, Biochimica et biophysica acta.

[68]  M. Roy,et al.  1H NMR spectrum of the native human insulin monomer. Evidence for conformational differences between the monomer and aggregated forms. , 1990, The Journal of biological chemistry.

[69]  D. Owens,et al.  Comparison of insulin analogue B9AspB27Glu and soluble human insulin in insulin-treated diabetes , 1990, The Lancet.

[70]  W. C. Johnson,et al.  Changes in secondary structure follow the dissociation of human insulin hexamers: A circular dichroism study , 1990, Proteins.

[71]  E. Kraegen,et al.  Quantitative Aspects of Subcutaneous Insulin Absorption , 1989, Diabetic medicine : a journal of the British Diabetic Association.

[72]  A. Vaag,et al.  NovoSol Basal: pharmacokinetics of a novel soluble long acting insulin analogue. , 1989, BMJ.

[73]  M. Dunn,et al.  Comparison of solution structural flexibility and zinc binding domains for insulin, proinsulin, and miniproinsulin. , 1989, Biochemistry.

[74]  E. Dodson,et al.  Phenol stabilizes more helix in a new symmetrical zinc insulin hexamer , 1989, Nature.

[75]  P. Home,et al.  Insulin treatment: a decade of change. , 1989, British medical bulletin.

[76]  D. Owens,et al.  Recombinant DNA derived monomeric insulin analogue: comparison with soluble human insulin in normal subjects. , 1988, BMJ.

[77]  T L Blundell,et al.  The structure of 2Zn pig insulin crystals at 1.5 A resolution. , 1988, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[78]  P. Hougaard,et al.  Soluble, prolonged-acting insulin derivatives. III. Degree of protraction, crystallizability and chemical stability of insulins substituted in positions A21, B13, B23, B27 and B30. , 1988, Protein engineering.

[79]  J. Brange,et al.  Monomeric insulins obtained by protein engineering and their medical implications , 1988, Nature.

[80]  K. Polonsky,et al.  Twenty-four-hour profiles and pulsatile patterns of insulin secretion in normal and obese subjects. , 1988, The Journal of clinical investigation.

[81]  L. Thim,et al.  BIOSYNTHESIS OF HUMAN INSULIN IN YEAST VIA SINGLE-CHAIN PRECURSORS , 1987 .

[82]  H. Kelders,et al.  GROWING-CRYSTALS BY ROBOTICS , 1987 .

[83]  P. Hougaard,et al.  Soluble, prolonged-acting insulin derivatives. II. Degree of protraction and crystallizability of insulins substituted in positions A17, B8, B13, B27 and B30. , 1987, Protein engineering.

[84]  P. Hougaard,et al.  Soluble, prolonged-acting insulin derivatives. I. Degree of protraction and crystallizability of insulins substituted in the termini of the B-chain. , 1987, Protein engineering.

[85]  R. Arakaki,et al.  The pharmacokinetics of subcutaneous regular insulin in type I diabetic patients: assessment using a glucose clamp technique. , 1986, The Journal of clinical endocrinology and metabolism.

[86]  L. Thim,et al.  Secretion and processing of insulin precursors in yeast. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[87]  T. M. Hayes,et al.  Human, Porcine and Bovine Ultralente Insulin: Subcutaneous Administration in Normal Man , 1986, Diabetic medicine : a journal of the British Diabetic Association.

[88]  K. Alberti,et al.  Human ultralente insulin: a comparison with porcine lente insulin as a twice-daily insulin in insulin-dependent diabetic patients with fasting hyperglycaemia. , 1986, Diabetes research.

[89]  G. Dimitriadis,et al.  Importance of Timing of Preprandial Subcutaneous Insulin Administration in the Management of Diabetes Mellitus , 1983, Diabetes Care.

[90]  K. Alberti,et al.  Continuous subcutaneous insulin infusion: comparison of plasma insulin profiles after infusion or bolus injection of the mealtime dose. , 1981, Metabolism: clinical and experimental.

[91]  J. A. Hoffmann,et al.  Chemical, Physical, and Biologic Properties of Biosynthetic Human Insulin , 1981, Diabetes Care.

[92]  R. Bilous,et al.  HUMAN INSULIN PRODUCED BY RECOMBINANT DNA TECHNOLOGY: SAFETY AND HYPOGLYCÆMIC POTENCY IN HEALTHY MEN , 1980, The Lancet.

[93]  M. Chou,et al.  Time-action characteristics of regular and NPH insulin in insulin-treated diabetics. , 1980, The Journal of clinical endocrinology and metabolism.

[94]  A. Riggs,et al.  Expression in Escherichia coli of chemically synthesized genes for human insulin. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[95]  J. Schlichtkrull.  THE ABSORPTION OF INSULIN , 1977, Acta paediatrica Scandinavica. Supplement.

[96]  W. Rutter,et al.  Rat insulin genes: construction of plasmids containing the coding sequences. , 1977, Science.

[97]  Tom L. Blundell,et al.  Insulin: The Structure in the Crystal and its Reflection in Chemistry and Biology by , 1972 .

[98]  Thomas Jh.  Electrophoresis of ( 35 S) sulphated insulin. Immunological and biological properties of the isolated electrophoretic components. , 1971 .

[99]  L. Winterscheid,et al.  Hypoglycemic activity and immunological half-life of porcine insulin and proinsulin in baboons and swine. , 1971, Endocrinology.

[100]  C. Binder.  Absorption of injected insulin. A clinical-pharmacological study. , 2009, Acta pharmacologica et toxicologica.

[101]  E. Baker,et al.  Structure of Rhombohedral 2 Zinc Insulin Crystals , 1969, Nature.

[102]  G. B. Dowling,et al.  Vitamin D in cutaneous tuberculosis. , 1947, Lancet.